Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

Acute Myeloid Leukemia Clinical Trial

Official title:

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04708054
• Other study ID #: 2020-0790
• Secondary ID: NCI-2020-1391920
• Status: Recruiting
• Phase: Phase 2
• Start date: October 21, 2021
• Est. completion date: December 31, 2027

Study information

• Verified date: June 2024
• Source: M.D. Anderson Cancer Center
• Contact: Uday R. Popat
• Phone: 713-745-3055
• Email: upopat[@]mdanderson.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase II trial studies the effect of venetoclax together with busulfan, cladribine, and fludarabine in treating patients with high-risk acute myeloid leukemia or myelodysplastic syndrome who are undergoing stem cell transplant. Chemotherapy drugs, such as venetoclax, busulfan, cladribine, and fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding venetoclax to the current standard of care stem cell transplant regimen of busulfan, fludarabine, and cladribine may help to control high-risk acute myeloid leukemia or myelodysplastic syndrome.

Description:

Phase 2 Portion

Primary Objective 1) To obtain preliminary evidence of efficacy as defined by 1-year progression free survival.

Secondary Objectives

To determine:

1. Safety of this regimen as per NCI toxicity criteria

2. Time to neutrophil and platelet engraftment

3. Incidence of acute and chronic GVHD

4. Relapse incidence

5. Non-relapse mortality

6. Overall survival

7. Graft versus host disease-relapse free survival (GRFS)

Phase 3 Portion

Primary Objective

1) To compare progression free survival between two arms Arm 1 Standard of Care: fludarabine + IV busulfan (FluBu) versus Arm 2 Experimental: Venetoclax + Fractionated busulfan, cladribine, and fludarabine

Secondary Objectives To compare following between two arms

1. Safety of this regimen as per NCI toxicity criteria

2. Time to neutrophil and platelet engraftment

3. Incidence of acute and chronic GVHD

4. Relapse incidence

5. Non-relapse mortality

6. Overall survival

7. Graft versus host disease-relapse free survival (GRFS)

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 324
• Est. completion date: December 31, 2027
• Est. primary completion date: December 31, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

Phase II

1. Age = 18 and = 70 years. English and non-English speaking participants are eligible.

2. Participants with acute myeloid leukemia who have previously received induction therapy and one of the following high-risk features:

1. ELN17 adverse risk prognostic group irrespective of remission status (see Appendix 2).

2. Measurable residual disease positive (MRD +)

3. Not in complete remission including complete remission without count recovery (Cri) and/or morphologic leukemia free state (MLFS), primary refractory, or relapsed disease. See Appendix 3 for details.

4. AML secondary to MDS or MPD

5. Therapy-related AML.

6. Not in complete remission after one course of induction therapy Or

Participants with myelodysplastic syndrome or CMML and one of the following high-risk features:

1. Poor or Very poor cytogenetic risk group as per IPSS-R

2. Mutated P53 or Ras pathway genes (CBL, NRAS, KRAS, NF1, PTPN1) or DNMT 3a or ASXL1 or RUNX1

3. Maximum IPSS-R >3.5 between diagnosis and the start of the preparative regimen.

4. = 5% BM blasts at transplant

5. Therapy-related MDS

3. HLA-identical sibling or a minimum of 7/8 matched unrelated donor, or a haploidentical related donor available

4. Participants must voluntarily sign an informed consent

5. Female participants of childbearing potential must have negative results for pregnancy test

6. Adequate hepatic and renal function per local laboratory reference range as follows:

• Aspartate transaminase (AST) and alanine transaminase (ALT) < 3.0X ULN

• Bilirubin <1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin)

• Participants must have adequate renal function as demonstrated by a creatinine clearance = 50 mL/min; calculated by the Cockcroft Gault formula or measured by 24 hours urine collection.

Phase III

1. Age = 18 and = 65 years. English and non-English speaking participants are eligible.

2. Participants with acute myeloid leukemia who have previously received induction therapy and one of the following high-risk features:

1. ELN22 adverse risk prognostic group irrespective of remission status (see Appendix 3).

2. Measurable residual disease positive (MRD +)

3. Not in complete remission including complete remission without count recovery (Cri) and/or morphologic leukemia free state (MLFS), primary refractory, or relapsed disease. See Appendix 4 for details.

4. AML secondary to MDS or MPD

5. Therapy-related AML.

6. Not in complete remission after one course of induction therapy Or

Patients with myelodysplastic syndrome and one of the following high-risk features:

1. Poor or Very poor cytogenetic risk group as per IPSS-R

2. Mutated P53 or Ras pathway genes (CBL, NRAS, KRAS, NF1, PTPN11) or ASXL1 or RUNX1

3. Maximum IPSS-R >3.5 between diagnosis and the start of the preparative regimen.

4. = 5% BM blasts at transplant

5. Therapy-related MDS Or Patients with CMML

3. HLA-identical sibling or a minimum of 8/8 matched unrelated donor

4. Participants must voluntarily sign an informed consent

5. Female participants of childbearing potential must have negative results for pregnancy test

6. Adequate hepatic and renal function per local laboratory reference range as follows:

• Aspartate transaminase (AST) and alanine transaminase (ALT) < 3.0X ULN

• Bilirubin <1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin)

• Participants must have adequate renal function as demonstrated by a creatinine clearance = 50 mL/min; calculated by the Cockcroft Gault formula or measured by 24 hours urine collection.

Exclusion criteria:

1. Participants is known to be positive for HIV.

2. Participants has cognitive impairments and/or is a prisoner.

3. Participants has acute promyelocytic leukemia

4. Participants has known active CNS involvement with AML.

5. Evidence of other clinically significant uncontrolled condition(s) including, but not limited to:

1. Uncontrolled and/or active systemic infection (viral, bacterial or fungal)

2. Chronic hepatitis B virus (HBV) or hepatitis C (HCV) requiring treatment. Note:

participants with serologic evidence of prior vaccination to HBV (i.e. hepatitis B surface (HBs) antigen negative-, anti-HBs antibody positive and anti-hepatitis B core (HBc) antibody negative) or positive anti-HBc antibody from intravenous immunoglobulins (IVIG) may participate.

6. Cardiac history of CHF requiring treatment or Ejection Fraction < 50% or unstable angina;

7. Corrected DLCO < 65% or FEV1 < 65%;

8. Administration or consumption of any of the following within 3 days prior to the first dose of study drug:

• grapefruit or grapefruit products

• Seville oranges (including marmalade containing Seville oranges)

• star fruit

9. Prior gemtuzumab ozogamicin and/or inotuzumab ozogamicin use

10. Participants with cognitive impairments and/or any serious unstable pre-existing medical condition or psychiatric disorder that can interfere with safety or with obtaining informed consent or compliance with study procedures.

11. Prior autologous or allogeneic stem cell transplantation.

Related Conditions & MeSH terms

• Acute Myeloid Leukemia
• Chronic Myelomonocytic Leukemia
• Leukemia
• Leukemia, Myelomonocytic, Chronic
• Leukemia, Myelomonocytic, Juvenile
• Myelodysplastic Syndrome
• Myelodysplastic Syndromes

Intervention

Drug:
• Busulfan
Given IV
• Cladribine
Given IV
• Fludarabine Phosphate
Given IV

Procedure:
• Hematopoietic Cell Transplantation
Undergo stem cell transplantation

Drug:
• Thiotepa
Given IV
• Venetoclax
Given PO

Locations

Country	Name	City	State
United States	M D Anderson Cancer Center	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
M.D. Anderson Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	1-year progression free survival (PFS)	The proportion of patients who are alive without disease relapse (PFS) at one year will be reported along with the corresponding 95% credible interval. Cox proportional hazards regression will be used to assess the association between PFS and clinical and treatment covariates of interest.	At 1 year post-transplant
Secondary	Overall survival (OS)	OS will be calculated from the time of transplant by the method of Kaplan and Meier.	Up to 3 years post-transplant
Secondary	Graft-versus (vs.)-host disease-free, relapse-free survival (GRFS)	GRFS will be calculated from the time of transplant by the method of Kaplan and Meier.	Up to 3 years post-transplant
Secondary	Time to platelet engraftment	The time to platelet engraftment will be calculated from the time of transplant and estimated by the Kaplan-Meier method.	From the time of transplant up to 3 years
Secondary	Time to neutrophil engraftment	The time to neutrophil engraftment will be calculated from the time of transplant and estimated by the Kaplan-Meier method.	From the time of transplant up to 3 years
Secondary	Incidence of acute and chronic graft-vs.-host disease (GvHD)	The cumulative incidence of acute and chronic GvHD with the competing risks of relapse and death will be estimated using the method of Gooley, and the method of Fine and Gray will be used to model the association between both parameters and clinical and treatment characteristics of interest.	Up to 3 years post-transplant
Secondary	Incidence of relapse and non-relapse mortality	The cumulative incidence of non-relapse mortality and relapse will also be assessed in a competing risks framework, with similar analyses performed.	Up to 3 years post-transplant
Secondary	Incidence of adverse events	Descriptive statistics will be used to summarize adverse events. The number and proportion of subjects with treatment emergent adverse events will be reported. All other safety parameters will be summarized using descriptive statistics or frequency counts. Graphical summaries will be used where appropriate.	Up to 3 years post-transplant

External Links

•   MD Anderson Cancer Center